Shareholders Unanimously Approve Agenda at SCHOTT Pharma's Inaugural AGM

SCHOTT Pharma AG & Co. KGaA successfully conducted its first Annual General Meeting (AGM) on March 14, 2024, garnering full approval from shareholders on all agenda items. The meeting, held virtually, allowed for interactive discussions between the shareholders and the company's management, reflecting on a year of significant achievements and outlining future strategies for growth and innovation. SCHOTT Pharma, a leading provider in the pharmaceutical packaging and delivery systems sector, marked a pivotal year by joining the SDAX index after its listing on the Frankfurt Stock Exchange in September 2023.

Demonstrating a solid financial performance in 2023 and a focused growth trajectory, the company emphasized its strategic shift towards high-value solutions catering to emerging pharmaceutical trends such as GLP-1, mRNA, and personalized medicine. CEO Andreas Reisse and CFO Dr. Almuth Steinkühler highlighted the company's commitment to innovation, capacity expansion in strategic markets like Europe and the USA, and the distribution of a EUR 0.15 per share dividend. These milestones underscore SCHOTT Pharma's position as a key partner in the pharmaceutical industry, driving forward sustainable and profitable growth.

The AGM outcomes showed overwhelming shareholder support, with near-unanimous votes in favor of the annual financial statements, dividend distribution, appointment of Ernst & Young GmbH as auditor, and confirmation of management and supervisory board actions. These results reflect strong confidence in SCHOTT Pharma's strategic direction and governance.